CN114470055A - External medicine formula for treating diabetic foot ulcer wound - Google Patents
External medicine formula for treating diabetic foot ulcer wound Download PDFInfo
- Publication number
- CN114470055A CN114470055A CN202210185171.0A CN202210185171A CN114470055A CN 114470055 A CN114470055 A CN 114470055A CN 202210185171 A CN202210185171 A CN 202210185171A CN 114470055 A CN114470055 A CN 114470055A
- Authority
- CN
- China
- Prior art keywords
- parts
- diabetic foot
- ginseng
- liquorice
- borneol
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003814 drug Substances 0.000 title claims abstract description 28
- 208000008960 Diabetic foot Diseases 0.000 title claims abstract description 27
- 208000027418 Wounds and injury Diseases 0.000 title claims abstract description 20
- 241000208340 Araliaceae Species 0.000 claims abstract description 28
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 claims abstract description 28
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 claims abstract description 28
- 235000003140 Panax quinquefolius Nutrition 0.000 claims abstract description 28
- 235000008434 ginseng Nutrition 0.000 claims abstract description 28
- DTGKSKDOIYIVQL-WEDXCCLWSA-N (+)-borneol Chemical compound C1C[C@@]2(C)[C@@H](O)C[C@@H]1C2(C)C DTGKSKDOIYIVQL-WEDXCCLWSA-N 0.000 claims abstract description 27
- REPVLJRCJUVQFA-UHFFFAOYSA-N (-)-isopinocampheol Natural products C1C(O)C(C)C2C(C)(C)C1C2 REPVLJRCJUVQFA-UHFFFAOYSA-N 0.000 claims abstract description 27
- 244000303040 Glycyrrhiza glabra Species 0.000 claims abstract description 27
- 229940116229 borneol Drugs 0.000 claims abstract description 27
- CKDOCTFBFTVPSN-UHFFFAOYSA-N borneol Natural products C1CC2(C)C(C)CC1C2(C)C CKDOCTFBFTVPSN-UHFFFAOYSA-N 0.000 claims abstract description 27
- DTGKSKDOIYIVQL-UHFFFAOYSA-N dl-isoborneol Natural products C1CC2(C)C(O)CC1C2(C)C DTGKSKDOIYIVQL-UHFFFAOYSA-N 0.000 claims abstract description 27
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 claims abstract description 27
- HTUMBQDCCIXGCV-UHFFFAOYSA-N lead oxide Chemical compound [O-2].[Pb+2] HTUMBQDCCIXGCV-UHFFFAOYSA-N 0.000 claims abstract description 27
- 235000011477 liquorice Nutrition 0.000 claims abstract description 27
- 241001676573 Minium Species 0.000 claims abstract description 25
- 241000037740 Coptis chinensis Species 0.000 claims abstract description 22
- 241000218691 Cupressaceae Species 0.000 claims abstract description 21
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 claims abstract description 13
- YEXPOXQUZXUXJW-UHFFFAOYSA-N lead(II) oxide Inorganic materials [Pb]=O YEXPOXQUZXUXJW-UHFFFAOYSA-N 0.000 claims abstract description 12
- 241000218202 Coptis Species 0.000 claims abstract description 7
- 235000002991 Coptis groenlandica Nutrition 0.000 claims abstract description 7
- 241000972672 Phellodendron Species 0.000 claims abstract description 6
- HPTYUNKZVDYXLP-UHFFFAOYSA-N aluminum;trihydroxy(trihydroxysilyloxy)silane;hydrate Chemical compound O.[Al].[Al].O[Si](O)(O)O[Si](O)(O)O HPTYUNKZVDYXLP-UHFFFAOYSA-N 0.000 claims description 15
- 229910052621 halloysite Inorganic materials 0.000 claims description 15
- 239000000843 powder Substances 0.000 claims description 13
- 239000000463 material Substances 0.000 claims description 11
- 238000000227 grinding Methods 0.000 claims description 6
- 238000002156 mixing Methods 0.000 claims description 6
- 239000000203 mixture Substances 0.000 claims description 6
- 238000005303 weighing Methods 0.000 claims description 6
- 238000001914 filtration Methods 0.000 claims description 3
- 239000011812 mixed powder Substances 0.000 claims description 3
- 238000002360 preparation method Methods 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 206010052428 Wound Diseases 0.000 claims 8
- 239000013583 drug formulation Substances 0.000 claims 7
- 238000000034 method Methods 0.000 claims 1
- 239000012049 topical pharmaceutical composition Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 16
- 230000035876 healing Effects 0.000 abstract description 6
- 230000001737 promoting effect Effects 0.000 abstract description 6
- 238000005469 granulation Methods 0.000 abstract description 5
- 230000003179 granulation Effects 0.000 abstract description 5
- 238000010926 purge Methods 0.000 abstract description 3
- 238000004458 analytical method Methods 0.000 abstract description 2
- 238000001035 drying Methods 0.000 abstract description 2
- 230000001338 necrotic effect Effects 0.000 abstract description 2
- 239000003053 toxin Substances 0.000 abstract description 2
- 231100000765 toxin Toxicity 0.000 abstract description 2
- 229940124350 antibacterial drug Drugs 0.000 description 5
- 244000052616 bacterial pathogen Species 0.000 description 5
- 206010012601 diabetes mellitus Diseases 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 231100000167 toxic agent Toxicity 0.000 description 4
- 239000003440 toxic substance Substances 0.000 description 4
- 206010059866 Drug resistance Diseases 0.000 description 3
- 238000009826 distribution Methods 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 230000001965 increasing effect Effects 0.000 description 3
- 206010062717 Increased upper airway secretion Diseases 0.000 description 2
- 238000002266 amputation Methods 0.000 description 2
- 230000002924 anti-infective effect Effects 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 210000003141 lower extremity Anatomy 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 208000026435 phlegm Diseases 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 1
- 240000008574 Capsicum frutescens Species 0.000 description 1
- 206010008531 Chills Diseases 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 208000003790 Foot Ulcer Diseases 0.000 description 1
- 206010017711 Gangrene Diseases 0.000 description 1
- 241000202807 Glycyrrhiza Species 0.000 description 1
- 235000001453 Glycyrrhiza echinata Nutrition 0.000 description 1
- 235000017382 Glycyrrhiza lepidota Nutrition 0.000 description 1
- 206010024774 Localised infection Diseases 0.000 description 1
- 241000475481 Nebula Species 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 208000005392 Spasm Diseases 0.000 description 1
- 208000009979 Traumatic Amputation Diseases 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 230000036461 convulsion Effects 0.000 description 1
- 230000007797 corrosion Effects 0.000 description 1
- 238000005260 corrosion Methods 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000004438 eyesight Effects 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 229940010454 licorice Drugs 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 244000045947 parasite Species 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 230000000171 quenching effect Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000004381 surface treatment Methods 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 230000035922 thirst Effects 0.000 description 1
- 230000002936 tranquilizing effect Effects 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/75—Rutaceae (Rue family)
- A61K36/756—Phellodendron, e.g. corktree
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/241—Lead; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/26—Iron; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
- A61K36/258—Panax (ginseng)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/484—Glycyrrhiza (licorice)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/71—Ranunculaceae (Buttercup family), e.g. larkspur, hepatica, hydrastis, columbine or goldenseal
- A61K36/718—Coptis (goldthread)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Botany (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Diabetes (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dermatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Inorganic Chemistry (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention relates to a formula of an external traditional Chinese medicine, in particular to a formula of an external medicine for treating diabetic foot ulcer wound surfaces, which comprises 10-20 parts of golden cypress, 10-20 parts of minium, 3-5 parts of borneol, 10-20 parts of litharge, 2-10 parts of liquorice, 5-10 parts of coptis chinensis, 5-10 parts of ginseng and 12-24 parts of red halloysite. The treatment principles obtained in the analysis of the prescription rule of the entropy clustering formula comprise toxin drawing, necrotic tissue removing, granulation promoting, heat clearing, detoxifying and sore healing and the like, for example, phellodendron and coptis root have the effects of clearing heat and drying dampness, purging fire and detoxifying, lithargite has the effects of healing sore and granulation promoting when being externally used, borneol has the effects of clearing heat, detoxifying and relieving pain, and the diabetic foot can be further treated by matching with minium, liquorice, coptis root, ginseng and red halloysite, and the treatment effect is improved.
Description
Technical Field
The invention relates to a formula of an external traditional Chinese medicine, in particular to a formula of an external medicine for treating diabetic foot ulcer wound surfaces.
Background
Diabetic foot refers to foot ulcers, infections and deep tissue destruction associated with lower limb distal nerve abnormalities and varying degrees of peripheral vasculopathy, is one of the most serious and most costly chronic complications of diabetes, and is the leading cause of non-traumatic amputation of diabetes. By 2040 years, the total number of diabetics reaches 6.42 hundred million, the risk of diabetic patients complicated with diabetic feet can reach 15 to 25 percent, and the ulcer recurrence rate, the re-amputation (toe) rate and the death rate of the diabetic feet after being cured still show an increasing trend year by year. The diabetes foot causes physiological pain to the patient, so that the life quality of the patient is greatly reduced, the psychological burden of the patient is increased when the patient is in danger of amputation of the lower limb, and meanwhile, the high treatment cost also causes huge economic burden. At present, the wound surface treatment of diabetic foot ulcer is mainly anti-infection, infection is one of the most important reasons for foot gangrene and disease deterioration of diabetic foot patients, the clinical manifestations of the infection are atypical, only 50% of patients have clinical manifestations, the patients can have typical systemic inflammatory manifestations such as fever, chilly, shivering and the like, and infected symptoms and physical signs such as red swelling and hot pain of foot skin and purulent secretion appearing on the wound surface. Effective anti-infection is a key measure for preventing the development of diseases, broad-spectrum antibiotics are preferred in the early treatment period, and after pathogens are determined, antibacterial drugs are adjusted according to drug sensitivity results.
However, in the current situation, with the application of broad-spectrum antibacterial drugs clinically and the unreasonable use of the antibacterial drugs outside the hospital of patients, the distribution and composition ratio of pathogenic bacteria also changes, the drug resistance of the pathogenic bacteria gradually rises, and part of the pathogenic bacteria form multi-drug resistant bacteria, so that the treatment difficulty is increased, and the illness state is difficult to control. In recent years, abuse of antibacterial drugs, mutation and spread of bacterial strain genes cause the drug resistance of the disease and the distribution of pathogenic bacteria to change correspondingly.
Disclosure of Invention
The invention aims to provide an external medicine formula for treating diabetic foot ulcer wound, which aims to solve the problem that the abuse of antibacterial drugs, the variation of bacterial strain genes and the transmission in the background technology cause the drug resistance of the disease and the distribution of pathogenic bacteria to be correspondingly changed. In order to achieve the purpose, the invention provides the following technical scheme: an external medicine formula for treating diabetic foot ulcer wound surfaces comprises, by weight, 10-20 parts of golden cypress, 10-20 parts of minium, 3-5 parts of borneol, 10-20 parts of litharge, 2-10 parts of liquorice, 5-10 parts of coptis chinensis, 5-10 parts of ginseng and 12-24 parts of red halloysite.
Preferably, the traditional Chinese medicine composition comprises, by weight, 10 parts of golden cypress, 10 parts of minium, 3 parts of borneol, 10 parts of lithargite, 2 parts of liquorice, 5 parts of coptis chinensis, 5 parts of ginseng and 12 parts of halloysite.
Preferably, the traditional Chinese medicine composition comprises, by weight, 10 parts of golden cypress, 10 parts of minium, 3 parts of borneol, 10 parts of lithargite, 2 parts of liquorice, 5 parts of coptis chinensis, 5 parts of ginseng and 12 parts of halloysite.
Preferably, the traditional Chinese medicine composition comprises 18 parts of golden cypress, 10 parts of minium, 5 parts of borneol, 20 parts of lithargite, 2 parts of liquorice, 5 parts of coptis chinensis, 10 parts of ginseng and 24 parts of halloysite.
Preferably, the traditional Chinese medicine composition comprises 12 parts of golden cypress, 18 parts of minium, 4 parts of borneol, 19 parts of lithargite, 3 parts of liquorice, 6 parts of coptis chinensis, 5 parts of ginseng and 20 parts of halloysite.
Preferably, 19 parts of golden cypress, 11 parts of minium, 4 parts of borneol, 11 parts of lithargite, 8 parts of liquorice, 6 parts of coptis chinensis, 6 parts of ginseng and 13 parts of red halloysite.
A preparation method of an external medicine formula for treating diabetic foot ulcer wound surfaces comprises the following steps:
firstly, preparing materials, namely weighing 10-20 parts of golden cypress, 10-20 parts of minium, 3-5 parts of borneol, 10-20 parts of litharge, 2-10 parts of liquorice, 5-10 parts of coptis chinensis, 5-10 parts of ginseng and 12-24 parts of halloysite by using a weighing device according to parts by weight;
secondly, grinding, namely grinding the prepared material in the first step into powder;
thirdly, mixing, namely adding the ground materials into a stirrer for fully mixing;
and fourthly, filtering the mixed powder by a filter, wherein the mesh number of a filter screen in the filter is 30 meshes, and the fineness of the filter screen is 0.595mm, and bottling the filtered powder to obtain the traditional Chinese medicine powder.
Preferably, the purity of the phellodendron, the minium, the borneol, the litharge, the liquorice, the coptis, the ginseng and the red halloysite is 100 percent.
The invention also provides application of the external medicine formula for treating the diabetic foot ulcer wound in preparing a medicine for treating diabetic foot.
Cortex Phellodendri has effects of clearing heat, eliminating dampness, clearing pathogenic fire, removing toxic substance, and treating sore.
The pill has effects of removing toxic substance, eliminating slough, eliminating dampness, healing sore, eliminating phlegm, and relieving convulsion.
Borneolum has effects of inducing resuscitation, refreshing mind, clearing away heat and toxic materials, improving eyesight, and removing nebula.
Lithargyrum has effects of eliminating dampness, killing parasite, removing toxic substance, astringing and preventing corrosion.
The licorice has the effects of tonifying spleen and qi, clearing away heat and toxic materials, eliminating phlegm and stopping cough, relieving spasm and pain, and harmonizing the medicines.
Rhizoma Coptidis has effects of clearing heat, eliminating dampness, purging pathogenic fire, and removing toxic substance.
Ginseng radix has effects of invigorating primordial qi, invigorating spleen, benefiting lung, promoting fluid production, quenching thirst, tranquilizing mind, and improving intelligence.
Halloysitum rubrum has effects of astringing intestine, stopping bleeding, promoting granulation, and healing sore.
Compared with the prior art, the invention has the beneficial effects that:
the treatment principles obtained in the analysis of the prescription rule of the entropy clustering formula comprise toxin drawing, necrotic tissue removing, granulation promoting, heat clearing, detoxifying and sore healing and the like, for example, phellodendron and coptis root have the effects of clearing heat and drying dampness, purging fire and detoxifying, lithargite has the effects of healing sore and granulation promoting when being externally used, borneol has the effects of clearing heat, detoxifying and relieving pain, and the diabetic foot can be further treated by matching with minium, liquorice, coptis root, ginseng and red halloysite, and the treatment effect is improved.
Detailed Description
The technical solutions in the embodiments of the present invention will be clearly and completely described below, and it is obvious that the described embodiments are only a part of the embodiments of the present invention, and not all embodiments. All other embodiments, which can be obtained by workers skilled in the art without any inventive work based on the embodiments of the present invention, are within the scope of the present invention.
The invention provides a technical scheme that: an external medicine formula for treating diabetic foot ulcer wound surfaces comprises, by weight, 10-20 parts of golden cypress, 10-20 parts of minium, 3-5 parts of borneol, 10-20 parts of litharge, 2-10 parts of liquorice, 5-10 parts of coptis chinensis, 5-10 parts of ginseng and 12-24 parts of red halloysite.
In the embodiment, by weight, 10 parts of golden cypress, 10 parts of minium, 3 parts of borneol, 10 parts of lithargite, 2 parts of liquorice, 5 parts of coptis chinensis, 5 parts of ginseng and 12 parts of halloysite.
In the embodiment, by weight, 15 parts of golden cypress, 15 parts of minium, 4 parts of borneol, 15 parts of lithargite, 6 parts of liquorice, 8 parts of coptis chinensis, 8 parts of ginseng and 18 parts of red halloysite.
In the embodiment, by weight, 18 parts of golden cypress, 10 parts of minium, 5 parts of borneol, 20 parts of lithargite, 2 parts of liquorice, 5 parts of coptis chinensis, 10 parts of ginseng and 24 parts of halloysite.
In the embodiment, by weight, 12 parts of golden cypress, 18 parts of minium, 4 parts of borneol, 19 parts of lithargite, 3 parts of liquorice, 6 parts of coptis chinensis, 5 parts of ginseng and 20 parts of red halloysite.
In the embodiment, by weight, 19 parts of golden cypress, 11 parts of minium, 4 parts of borneol, 11 parts of lithargite, 8 parts of liquorice, 6 parts of coptis chinensis, 6 parts of ginseng and 13 parts of red halloysite.
The embodiment also provides a preparation method of the external medicine formula for treating diabetic foot ulcer wound, which comprises the following steps:
firstly, preparing materials, namely weighing 10-20 parts of golden cypress, 10-20 parts of minium, 3-5 parts of borneol, 10-20 parts of litharge, 2-10 parts of liquorice, 5-10 parts of coptis chinensis, 5-10 parts of ginseng and 12-24 parts of halloysite by using a weighing device according to parts by weight;
secondly, grinding, namely grinding the prepared material in the first step into powder;
thirdly, mixing, namely adding the ground materials into a stirrer for fully mixing;
and fourthly, filtering the mixed powder by a filter, wherein the mesh number of a filter screen in the filter is 30 meshes, and the fineness of the filter screen is 0.595mm, and bottling the filtered powder to obtain the traditional Chinese medicine powder.
In this example, the purity of phellodendron, red lead, borneol, litharge, liquorice, coptis, ginseng and halloysite is 100%.
When in use, 5 parts of the traditional Chinese medicine powder is mixed with the powder water and fully stirred uniformly, the wet medicinal powder is smeared on an affected part, and finally the bandage or gauze is used for binding the wet traditional Chinese medicine powder on the affected part, so that the purpose of external application can be achieved.
The foregoing shows and describes the general principles, essential features, and advantages of the invention. The scope of the invention is defined by the appended claims and equivalents thereof.
Claims (9)
1. An external medicine formula for treating diabetic foot ulcer wound surfaces is characterized in that: 10-20 parts of golden cypress, 10-20 parts of minium, 3-5 parts of borneol, 10-20 parts of litharge, 2-10 parts of liquorice, 5-10 parts of coptis chinensis, 5-10 parts of ginseng and 12-24 parts of red halloysite.
2. The external use drug formulation for treating diabetic foot ulcer wounds as claimed in claim 1, characterized in that: the traditional Chinese medicine composition comprises, by weight, 10 parts of golden cypress, 10 parts of minium, 3 parts of borneol, 10 parts of litharge, 2 parts of liquorice, 5 parts of coptis chinensis, 5 parts of ginseng and 12 parts of halloysite.
3. The external use drug formulation for treating diabetic foot ulcer wounds as claimed in claim 1, characterized in that: 15 parts of golden cypress, 15 parts of minium, 4 parts of borneol, 15 parts of lithargite, 6 parts of liquorice, 8 parts of coptis chinensis, 8 parts of ginseng and 18 parts of halloysite.
4. The external use drug formulation for treating diabetic foot ulcer wounds as claimed in claim 1, characterized in that: 18 parts of phellodendron, 10 parts of minium, 5 parts of borneol, 20 parts of litharge, 2 parts of liquorice, 5 parts of coptis chinensis, 10 parts of ginseng and 24 parts of red halloysite.
5. The external use drug formulation for treating diabetic foot ulcer wounds as claimed in claim 1, characterized in that: 12 parts of golden cypress, 18 parts of minium, 4 parts of borneol, 19 parts of lithargite, 3 parts of liquorice, 6 parts of coptis chinensis, 5 parts of ginseng and 20 parts of halloysite.
6. The external use drug formulation for treating diabetic foot ulcer wounds as claimed in claim 1, characterized in that: 19 parts of golden cypress, 11 parts of minium, 4 parts of borneol, 11 parts of lithargite, 8 parts of liquorice, 6 parts of coptis chinensis, 6 parts of ginseng and 13 parts of halloysite.
7. A method for preparing the external-use drug formulation for treating diabetic foot ulcer wounds as claimed in any one of claims 1 to 6, which is characterized in that: the preparation method comprises the following steps:
firstly, preparing materials, namely weighing 10-20 parts of golden cypress, 10-20 parts of minium, 3-5 parts of borneol, 10-20 parts of litharge, 2-10 parts of liquorice, 5-10 parts of coptis chinensis, 5-10 parts of ginseng and 12-24 parts of halloysite by using a weighing device according to parts by weight;
secondly, grinding, namely grinding the prepared material in the first step into powder;
thirdly, mixing, namely adding the ground materials into a stirrer for fully mixing;
and fourthly, filtering the mixed powder by a filter, wherein the mesh number of a filter screen in the filter is 30 meshes, and the fineness of the filter screen is 0.595mm, and bottling the filtered powder to obtain the traditional Chinese medicine powder.
8. The external use drug formulation for treating diabetic foot ulcer wounds as claimed in claim 1, characterized in that: the purity of phellodendron, red lead, borneol, litharge, liquorice, coptis, ginseng and halloysite is 100 percent.
9. The use of the topical formulation as claimed in any one of claims 1 to 6 for the manufacture of a medicament for the treatment of diabetic foot ulcers.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210185171.0A CN114470055A (en) | 2022-02-28 | 2022-02-28 | External medicine formula for treating diabetic foot ulcer wound |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210185171.0A CN114470055A (en) | 2022-02-28 | 2022-02-28 | External medicine formula for treating diabetic foot ulcer wound |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN114470055A true CN114470055A (en) | 2022-05-13 |
Family
ID=81484990
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202210185171.0A Pending CN114470055A (en) | 2022-02-28 | 2022-02-28 | External medicine formula for treating diabetic foot ulcer wound |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN114470055A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN115737720A (en) * | 2022-11-25 | 2023-03-07 | 麦莩医疗器械(武汉)有限公司 | Antibacterial paste composition and preparation method and application thereof |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105381051A (en) * | 2015-12-10 | 2016-03-09 | 袁明东 | Traditional Chinese medicinal combined medicine for treating non-amputation long-term disunion of diabetic foot and preparation method of traditional Chinese medicinal combined medicine |
| CN105943675A (en) * | 2016-06-01 | 2016-09-21 | 杨振铎 | Traditional Chinese medicine ointment for treating diabetic foot and preparation method thereof |
-
2022
- 2022-02-28 CN CN202210185171.0A patent/CN114470055A/en active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105381051A (en) * | 2015-12-10 | 2016-03-09 | 袁明东 | Traditional Chinese medicinal combined medicine for treating non-amputation long-term disunion of diabetic foot and preparation method of traditional Chinese medicinal combined medicine |
| CN105943675A (en) * | 2016-06-01 | 2016-09-21 | 杨振铎 | Traditional Chinese medicine ointment for treating diabetic foot and preparation method thereof |
Non-Patent Citations (4)
| Title |
|---|
| 佚名: "外敷中药治疗糖尿病足溃疡", 《百度》 * |
| 王长璐等: "中医外治糖尿病足溃疡的治疗现状", 《北京中医药》 * |
| 祝娉婷等: "冰黄凝胶治疗糖尿病足的作用及机理研究", 《实用临床医药杂志》 * |
| 韩瑞英等: "灸药并用治疗糖尿病足32例", 《安徽中医学院学报》 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN115737720A (en) * | 2022-11-25 | 2023-03-07 | 麦莩医疗器械(武汉)有限公司 | Antibacterial paste composition and preparation method and application thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103656372B (en) | Diabetic foot ointment | |
| CN114470055A (en) | External medicine formula for treating diabetic foot ulcer wound | |
| CN101919927B (en) | Spray for promoting scald healing | |
| CN104800700B (en) | It is a kind of to treat dermopathic herbal composite | |
| CN102357164B (en) | Medicine composition for clinical care of burns and preparation method thereof | |
| CN1557286A (en) | Compound chlorhexidine acetate spray | |
| CN102283896A (en) | Drug for curing chronic allergic rhinitis | |
| CN101732591B (en) | Sores plaster | |
| CN101934032B (en) | Chinese medicinal compound external preparation for treating diabetes and preparation method and application thereof | |
| CN114177231B (en) | Antipyretic pharmaceutical composition, antipyretic gel and preparation method | |
| CN1294931C (en) | Compound collunarium oil and preparation method thereof | |
| CN1125139A (en) | Antiphlogistic analgesic ointment for treating burn | |
| CN111759890A (en) | Ointment for treating wound healing and preparation method thereof | |
| CN100488547C (en) | Pharmaceutical composition for treating tinea and complication thereof | |
| CN102499961B (en) | Traditional Chinese medicinal composition drug for external use for treating ecthyma and preparation method thereof | |
| CN1175850C (en) | Medicine for treating burns and scald, and producing method thereof | |
| CN105168503B (en) | It is a kind of to be used to prevent external medicine composition of radiodermatitis and preparation method thereof | |
| CN103006932A (en) | Medicinal liquor with Miao formula for effectively treating traumatic infection and traumatic treatment | |
| CN115400174B (en) | External washing formula for acute eczema and preparation method thereof | |
| CN103083445A (en) | Traditional Chinese medicine preparation used for treating skin ulcers, and preparation method thereof | |
| CN115381883A (en) | Wuhuang burn sore paste and preparation method thereof | |
| CN1065137C (en) | Liniment made of traditional Chinese medicine for treating pharyngitis, and prepn. method therefor | |
| CN1857543A (en) | Externally applied Chinese medicine liniment for treating skin diseases | |
| CN104367763A (en) | Traditional Chinese medicine for treating diabetic foot | |
| CN114917303A (en) | Traditional Chinese medicine composition for treating rhinitis and preparation method and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20220513 |
|
| RJ01 | Rejection of invention patent application after publication |